Cat. No.: HY-B0260

Methylprednisolone

(Synonyms: U 7532)

19 Cited Publications

Customer Review

Based on 19 publication(s) in Google Scholar

Methylprednisolone (U 7532) is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.

For research use only. We do not sell to patients.

Purity: 99.78%
CAS No.: 83-43-2
Formula: C₂₂H₃₀O₅
Molecular Weight:374.47

Storage:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Methylprednisolone Chemical Structure

CAS No.: 83-43-2

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Induced Disease Models
- Clinical Trial
Chemical Information
Publications (19)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

Glucocorticoid Receptor

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	EC₅₀	12.6 μM Compound: 6-alpha-Methylprednisolone	Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	4 μM Compound: 6-alpha-Methylprednisolone	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]

In Vitro

Methylprednisolone is commonly used for anti-inflammatory purposes. Methylprednisolone can be used in the study of bronchial inflammation or acute bronchitis caused by arthritis and various respiratory diseases^[1].
Methylprednisolone can improve neurological recovery in acute spinal cord injury^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Based on the blood and multi-tissue concentration-time curves of Methylprednisolone in rats, its tissue distribution was found to be nonlinear, with the highest content in the liver (322.9 ng/ml) and the lowest content in fat (2.74 ng/ml). Due to P-glycoprotein-mediated blood-brain barrier (BBB) efflux transport, Methylprednisolone is poorly distributed in the central nervous system^[5].
Methylprednisolone can be used in animal modeling to construct a femoral head necrosis model.

1. Induced osteonecrosis^[4]

Background

Methylprednisolone triggers osteoblast death through multiple pathways such as mitochondrial autophagy, ferroptosis and apoptosis, inducing femoral head necrosis.

Specific Modeling Methods

SD Rats • male • 10 weeks old
Administration: 30 mg/kg • im • Injection on the second, third and fourth day

Modeling Indicators

Molecular changes: The bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular spacing (Tb.Sp) of the femoral head of rats were significantly reduced.

Phenotypic observation: HE staining evaluation showed an increase in empty pits in rats.

Correlated Product(s) Dexamethasone (HY-14648)

Opposite Product(s) XJB-5-131 (HY-129460)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 83-43-2
Appearance Solid
Molecular Weight 374.47
Formula C₂₂H₃₀O₅
Color White to off-white
SMILES

O=C1C=C[C@]2(C)[C@@]3([H])[C@@H](O)C[C@]4(C)[C@@](O)(C(CO)=O)CC[C@@]4([H])[C@]3([H])C[C@H](C)C2=C1
Synonyms

U 7532
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (19)

All Histological Imaging/StainingIn Vivo Efficacy StudyRT-PCRWB

Sort by:

Journal Impact Factor

Bone Res

Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis. [Abstract]

2025 Jan 26;13(1):18. PMID: 39865068
Chem Eng J

2026 Mar 3.
Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Int J Biol Sci

Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. [Abstract]

2020 Jun 27;16(13):2382-2391. PMID: 32760206

Methylprednisolone purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2020 Jun 27;16(13):2382-2391. [Abstract]

After treatment of GES-1 cells with 100 nM glucocorticoids or chemicals for 48 h, the protein expression levels of ACE2 is examined. Compared to the blank control, Methylprednisolone reveals an activating effect on ACE2 expression.
Redox Rep

Monoammonium glycyrrhizinate ameliorates mitochondrial dysfunction-mediated oxidative stress and neuroinflammation via the NRF2/NQO1 axis after spinal cord injury. [Abstract]

2025 Dec;30(1):2585221. PMID: 41240391

Methylprednisolone purchased from MedChemExpress. Usage Cited in: Redox Rep. 2025 Dec;30(1):2585221. [Abstract]

Methylprednisolone (30 mg/kg; ip).Histopathological staining (HE) of spinal cord tissues at 28 dpi.
Blood Adv

Differential effects of GVHD therapies on intestinal epithelium. [Abstract]

2026 Feb 5:bloodadvances.2025017189. PMID: 41643175
Mol Med

Inhibition of insulin degrading enzyme suppresses osteoclast hyperactivity via enhancing Nrf2-dependent antioxidant response in glucocorticoid-induced osteonecrosis of the femoral head. [Abstract]

2024 Jul 31;30(1):111. PMID: 39085816
Biochem Pharmacol

Irisin alleviates steroid-induced vascular dysfunction by regulating the αVβ5-c-Abl-Caveolin-1 signaling pathway. [Abstract]

2025 Jun:236:116870. PMID: 40086515
Commun Biol

Pentraxin 3 ameliorates glucocorticoid-induced osteonecrosis of the femoral head via TLR4/NF-κB/FGF21 signaling axis. [Abstract]

2025 Dec 2;9(1):27. PMID: 41331332

Methylprednisolone purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Dec 2;9(1):27. [Abstract]

Flowchart of ONFH model on Ptx3-KO and wild-type mice.
Commun Biol

GDF11 alleviates glucocorticoid-induced osteonecrosis of the femoral head by regulating angiogenesis via the PI3K-AKT-eNOS pathway. [Abstract]

2025 Nov 25;8(1):1682. PMID: 41291036

Methylprednisolone purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Nov 25;8(1):1682. [Abstract]

The expression of GDF11, CD31 and VEGFA in the control group (untreated), Methylprednisolone (MP: 100 μM; 24 h) treatment group and MP+GDF11 treatment group (n=3 in each group) was detected by real-time quantitative PCR.

Methylprednisolone purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Nov 25;8(1):1682. [Abstract]

Western blotting was performed to detect expression of PI3K, AKT, eNOS, p-PI3K, p-AKT, and p-eNOS in the following groups: Methylprednisolone (MP: 100 μM; 24 h), MP + GDF11-treated, MP + GDF11 + LY294002-treated, and MP + GDF11 + L-NAME-treated cells.
Drug Des Devel Ther

ED-71 Prevents Glucocorticoid-Induced Osteoporosis by Regulating Osteoblast Differentiation via Notch and Wnt/β-Catenin Pathways. [Abstract]

2022 Nov 15:16:3929-3946. PMID: 36411860
iScience

2023 Apr 5,23.
Biomedicines

Kaempferol Alleviates Glucocorticoid-Induced Osteonecrosis of the Femoral Head by Modulating Macrophage M1/M2 Polarization Through RhoA/ROCK-Mediated Mitophagy Activation. [Abstract]

2026 Feb 9;14(2):400. PMID: 41751299
Sci Rep

New insights into the mechanism of microvascular rarefaction via endothelial-mesenchymal transition in steroid-induced osteonecrosis of femoral head. [Abstract]

2025 Dec 15;16(1):986. PMID: 41398023
Mol Med Rep

NEDD4 regulates VEGF signaling and mTOR to promote angiogenesis and the cell cycle in steroid‑induced osteonecrosis of the femoral head. [Abstract]

2026 Jan;33(1):49. PMID: 41268613
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
BMC Pulm Med

Effects of different doses of methylprednisolone therapy on acute respiratory distress syndrome: results from animal and clinical studies. [Abstract]

2022 Sep 16;22(1):348. PMID: 36114531
Drug Test Anal

High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]

2021 Feb;13(2):283-298. PMID: 32852861
PLoS One

PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions. [Abstract]

2025 Jun 20;20(6):e0325190. PMID: 40540523

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (333.81 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6704 mL

13.3522 mL

26.7044 mL

5 mM

0.5341 mL

2.6704 mL

5.3409 mL

10 mM

0.2670 mL

1.3352 mL

2.6704 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 25 mg/mL (66.76 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Strupp, M., et al., Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med, 2004. 351(4): p. 354-61. [Content Brief]

[2]. Bracken, M.B., et al., A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med, 1990. 322(20): p. 1405-11. [Content Brief]

[3]. Zhen Xiang, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci 2020; 16(13):2382-2391.

[4]. Fan Y,et al. Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis. Bone Res. 2025 Jan 26;13(1):18. [Content Brief]

[5]. Yu R, et al. Physiologically Based Pharmacokinetic Modeling: The Reversible Metabolism and Tissue-Specific Partitioning of Methylprednisolone and Methylprednisone in Rats. Drug Metab Dispos. 2024 Jun 17;52(7):662-672. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6704 mL	13.3522 mL	26.7044 mL	66.7610 mL
	5 mM	0.5341 mL	2.6704 mL	5.3409 mL	13.3522 mL
	10 mM	0.2670 mL	1.3352 mL	2.6704 mL	6.6761 mL
	15 mM	0.1780 mL	0.8901 mL	1.7803 mL	4.4507 mL
	20 mM	0.1335 mL	0.6676 mL	1.3352 mL	3.3381 mL
	25 mM	0.1068 mL	0.5341 mL	1.0682 mL	2.6704 mL
	30 mM	0.0890 mL	0.4451 mL	0.8901 mL	2.2254 mL
	40 mM	0.0668 mL	0.3338 mL	0.6676 mL	1.6690 mL
	50 mM	0.0534 mL	0.2670 mL	0.5341 mL	1.3352 mL
	60 mM	0.0445 mL	0.2225 mL	0.4451 mL	1.1127 mL
	80 mM	0.0334 mL	0.1669 mL	0.3338 mL	0.8345 mL
	100 mM	0.0267 mL	0.1335 mL	0.2670 mL	0.6676 mL

Keywords

Methylprednisolone

19 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Methylprednisolone

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Anti-Cardiovascular Disease Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Antidepressant Compound Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Animal Drug Library

Steroid Hormones Library

Publications Citing Use of MedChemExpress (MCE) Methylprednisolone

Biological Activity

Chemical Information

Publications (19)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Methylprednisolone Related Classifications

Cat. No.: HY-B0260